Weight Management with Multiple Endocrine Neoplasia (MEN1 & MEN2) in South Africa

Multiple Endocrine Neoplasia (MEN) syndromes are rare hereditary tumour syndromes in which mutations in specific genes predispose individuals to develop tumours — typically benign but sometimes malignant — affecting multiple endocrine glands simultaneously. MEN type 1 (MEN1; MEN1 gene mutation) classically causes tumours of the parathyroid glands, anterior pituitary, and pancreatic/duodenal neuroendocrine cells (gastrinomas, insulinomas). MEN type 2 (MEN2; RET proto-oncogene mutation) encompasses MEN2A (medullary thyroid carcinoma, phaeochromocytoma, hyperparathyroidism) and MEN2B (medullary thyroid carcinoma, phaeochromocytoma, mucosal neuromas, Marfanoid habitus). MEN type 4 (MEN4; CDKN1B mutation) resembles MEN1 and is increasingly recognised. These are autosomal dominant conditions, meaning a first-degree relative of an affected person has a 50% chance of carrying the mutation. In South Africa, MEN syndromes are managed at academic hospitals by endocrinologists and surgeons, often in coordination with genetic counselling services. Weight management in MEN is uniquely complex because each tumour type produces its own hormonal disturbance — and patients may have multiple active tumours simultaneously, each pulling body weight in different directions. Surgery, radiation, and pharmacotherapy further alter metabolic state. This guide addresses the weight-relevant aspects of each major MEN component.

MEN1 Overview: The Three P's

MEN1 is often remembered by the "three P's" of affected glands:

Component Prevalence in MEN1 Hormones Excess/Deficient Weight Effect
Parathyroid tumours (hyperparathyroidism) >95% PTH excess leading to hypercalcaemia Fatigue, muscle weakness, depression — all reduce activity; nephrolithiasis complications
Pancreatic/duodenal neuroendocrine tumours (pNETs) 30–80% Gastrin excess (gastrinoma) causing ulcers and diarrhoea; insulin excess (insulinoma) causing hypoglycaemia Gastrinoma: malabsorption, diarrhoea, weight loss; Insulinoma: hypoglycaemia-driven overeating leading to weight gain
Pituitary tumours (adenomas) 30–40% Prolactin excess (prolactinoma most common); GH excess (acromegaly); ACTH excess (Cushing's disease) Prolactinoma: weight gain, metabolic syndrome; Acromegaly: muscle/organ mass increase; Cushing's: central obesity

MEN2 Overview

MEN2 Type Components Weight-Relevant Features
MEN2A Medullary thyroid carcinoma (MTC; 95%), phaeochromocytoma (40–50%), primary hyperparathyroidism (15–30%) MTC: calcitonin-driven diarrhoea, weight loss; Phaeochromocytoma: catecholamine excess, metabolic rate elevation, cardiovascular risk; Hyperparathyroidism: fatigue, bone loss
MEN2B MTC (earliest onset, most aggressive), phaeochromocytoma, mucosal neuromas, Marfanoid habitus, intestinal ganglioneuromas Very thin Marfanoid habitus; intestinal ganglioneuromas cause chronic diarrhoea and malabsorption; weight maintenance is often the challenge, not weight loss
Familial MTC MTC only (RET mutation without phaeochromocytoma or hyperparathyroidism) Post-thyroidectomy hypothyroidism if under-replaced; MTC calcitonin-driven diarrhoea if bulky metastatic disease

Weight Implications by Tumour Type

1. Primary Hyperparathyroidism (Parathyroid Adenomas)

Primary hyperparathyroidism (PHPT) from parathyroid tumours is the most common MEN1 feature. Excess parathyroid hormone (PTH) elevates serum calcium. The effects on weight and body composition are largely indirect:

After successful parathyroid surgery, calcium normalises. Patients typically report significant improvement in energy, mood, and cognitive function — facilitating return to normal physical activity and dietary self-regulation. Many experience spontaneous weight normalisation following successful parathyroidectomy.

Calcium Restriction Is NOT Recommended in PHPT: A common misconception is that restricting dietary calcium reduces blood calcium in primary hyperparathyroidism. This is incorrect and potentially harmful — PTH continues to mobilise calcium from bones regardless of dietary intake, and very low calcium diets may actually stimulate more PTH secretion. Maintain normal dietary calcium (1,000–1,200 mg/day from food sources). Avoid calcium supplements unless directed by your specialist. Stay very well hydrated — 2.5 litres of water daily — to reduce kidney stone risk.

2. Gastrinoma (Zollinger-Ellison Syndrome) in MEN1

Gastrinomas are the most common pancreatic neuroendocrine tumour in MEN1 and cause Zollinger-Ellison Syndrome (ZES) — massive gastric acid hypersecretion driving peptic ulcers and secretory diarrhoea.

Medical management: High-dose proton pump inhibitors (PPIs — omeprazole, pantoprazole, esomeprazole) are first-line and dramatically reduce acid hypersecretion. Effective PPI therapy reduces diarrhoea and allows nutritional recovery. Somatostatin analogues (octreotide, lanreotide — Somatuline Autogel, available in SA through specialty pharmacies) are used to control hormone secretion and may stabilise tumour growth.

Diet During Active ZES: Small, frequent meals rather than large meals; low-fat diet to reduce diarrhoea; avoid foods that stimulate acid (spicy food, coffee, alcohol); supplement fat-soluble vitamins; ensure adequate calcium and magnesium (chronic PPI use over years depletes these minerals).

3. Insulinoma in MEN1

Insulinomas secrete insulin autonomously, causing recurrent hypoglycaemia. The weight effect of insulinoma is almost uniformly weight gain:

4. Pituitary Tumours in MEN1

Each pituitary tumour type has distinct weight effects:

Pituitary Tumour Hormone Excess Weight Effect Treatment Implications
Prolactinoma (most common) Prolactin excess Weight gain; metabolic syndrome; reduced libido; in women: amenorrhoea and oestrogen deficiency leading to bone loss Dopamine agonists (cabergoline, bromocriptine) reduce prolactin and often improve weight; both available in SA
Somatotroph adenoma (acromegaly) Growth hormone and IGF-1 excess Increased organ and muscle mass; soft tissue swelling; insulin resistance; visceral fat accumulation; significant cardiovascular risk Surgery (transsphenoidal), somatostatin analogues (octreotide/lanreotide), pegvisomant (GH receptor antagonist) — metabolic improvement follows hormone control
Corticotroph adenoma (Cushing's disease) ACTH driving cortisol excess Central (truncal/visceral) obesity; moon face; buffalo hump; muscle wasting; hypertension; diabetes; osteoporosis — classic Cushing's syndrome features Surgery first-line; pasireotide (Signifor) second-line; bilateral adrenalectomy as last resort; post-remission weight management focuses on reversing glucocorticoid-induced changes
Non-functioning adenoma Mass effect compressing normal pituitary Hypopituitarism causing GH deficiency, hypothyroidism, secondary adrenal insufficiency, hypogonadism — all cause fatigue, weight gain, reduced muscle mass Hormone replacement therapy (thyroxine, hydrocortisone, testosterone/oestrogen, GH if indicated) combined with diet and exercise

5. Phaeochromocytoma in MEN2

Phaeochromocytomas are catecholamine-secreting tumours of the adrenal medulla, occurring in 40–50% of MEN2A and most MEN2B patients. Their metabolic effects are dramatic:

Phaeochromocytoma and Exercise: High-intensity exercise can trigger dangerous hypertensive crises in uncontrolled phaeochromocytoma. Until the tumour is surgically removed and blood pressure is controlled with alpha-blockers (phenoxybenzamine, doxazosin) followed by beta-blockers, vigorous exercise must be avoided. Walking and gentle yoga are generally acceptable with medical clearance.

Dietary considerations with phaeochromocytoma: Tyramine-rich foods can theoretically trigger catecholamine release. During the pre-operative period, moderate the intake of: aged cheeses, fermented meats, red wine, soy sauce, overripe fruits. In South Africa, this means limiting heavily aged cheeses, some aged biltong, certain red wines, and soy-based condiments until after successful surgery.

6. Medullary Thyroid Carcinoma (MTC) in MEN2

MTC secretes calcitonin and sometimes other peptides including CGRP and serotonin. Effects on weight:

Post-Surgical Nutrition in MEN

MEN patients often undergo multiple surgeries over their lifetime. Nutritional recovery after endocrine surgery depends on the procedure:

Surgery Key Nutritional Consideration SA-Specific Tips
Parathyroidectomy "Hungry bone" syndrome — rapid calcium uptake by bones post-surgery; requires high calcium and vitamin D supplementation Amasi (fermented milk), sardines, calcium supplements; daily sun exposure for D3 production; fortified plant milks from Pick n Pay or Woolworths
Distal pancreatectomy (insulinoma) Risk of exocrine pancreatic insufficiency (fat malabsorption); may develop new-onset diabetes Pancreatic enzyme replacement (Creon) with all fat-containing meals; low-fat diet initially; regular blood glucose monitoring
Whipple procedure (pancreaticoduodenectomy) Severe malabsorption; pancreatic enzyme deficiency; diabetes; dumping syndrome Small frequent meals; Creon with every meal; avoid high-sugar drinks immediately after meals (dumping); specialist dietitian input is essential
Total thyroidectomy (MTC) Lifelong levothyroxine; risk of hypoparathyroidism causing hypocalcaemia post-operatively Watch for post-op tingling/tetany (hypocalcaemia signs); calcium and active vitamin D (calcitriol) supplementation acutely; lifelong levothyroxine adherence critical
Adrenalectomy (phaeochromocytoma) If bilateral: permanent adrenal insufficiency requiring lifelong hydrocortisone and fludrocortisone Carry emergency hydrocortisone injection; wear medic alert bracelet; sick day rules are essential for life
Transsphenoidal surgery (pituitary) Transient diabetes insipidus (DI), SIADH, or hormone deficiencies; monitor fluid balance closely Fluids monitored by hospital team post-operatively; long-term pituitary hormone replacement as indicated

General Diet and Lifestyle Approach for MEN Patients

Given the multi-system nature of MEN and the multiple concurrent hormonal disturbances, several general principles apply broadly:

Genetic Testing and Family Surveillance

MEN1 and MEN2 are hereditary — if you or a family member has been diagnosed, action is needed for the whole family:

MEN Support and Resources in South Africa

Navigating weight management with a complex endocrine tumour syndrome?
We cover the full spectrum of hormonal and metabolic conditions affecting weight in South Africa.
Browse all our specialist guides at WeightLossDiets.co.za

Key Takeaways